# Enoxaparin Thromboprophylaxis in Cancer Patients With Elevated Tissue Factor Bearing Microparticles

> **NCT00908960** · PHASE2 · COMPLETED · sponsor: **Beth Israel Deaconess Medical Center** · enrollment: 70 (actual)

## Conditions studied

- Advanced Pancreatic, Colon, Lung, Gastric and Ovarian Cancer

## Interventions

- **DRUG:** Enoxaparin

## Key facts

- **NCT ID:** NCT00908960
- **Lead sponsor:** Beth Israel Deaconess Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-05
- **Primary completion:** 2012-04
- **Final completion:** 2012-10
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2017-12-19

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00908960

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00908960, "Enoxaparin Thromboprophylaxis in Cancer Patients With Elevated Tissue Factor Bearing Microparticles". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00908960. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*